Coronavirus Penny Stocks Are Surging Right Now
Call it hype, call it a YOLO, but whatever you label them, coronavirus penny stocks are some of the most popular in the market right now. It seems like every day we see a new crop emerge. At the same time, we see past performers gain more ground. But if you dare to brave the land of COVID-19 stocks, be prepared for volatility.
These aren’t the cool, calm, steady climbing dividend stocks your grandfather bought in his day. These stocks will jump up hundreds of percentage points within a matter of days or even hours. Many will plummet back down to where they started from or even lower.
[Special Report] Where is The Golden Opportunity Right Now?
But this doesn’t mean all coronavirus penny stocks are wild west, shoot-from-the-hip, stocks. Some have actually built a model around sustained business operations specifically for treating viral infections. On the flip side, we’re also seeing plenty of companies grasp at straws to gain some type of exposure to the virus or “viruses like COVID-19”.
Regardless of the risks, if you can handle wild swings and some of the highest levels of volatility, some of these stocks may find themselves on your watch list this week/month. There’s a high likelihood that we’ll be hearing about coronavirus stocks for at least a little while longer. So as new updates come up, so too could speculative penny stocks as you’ll see on this list.
Coronavirus Penny Stocks to Buy [or avoid]: Heat Biologics
Heat Biologics (HTBX-Stock Report)was one o the coronavirus penny stocks we discussed on March 16. The latest move comes on the heels of new figures on coronavirus cases across the world. Recently the company began a coronavirus vaccine program and announced that it engaged a government relations firm to advance collaboration efforts. The goal is to secure government funding for its program.
Meanwhile, this week, Heat reported that it was invited to join the Alliance for Biosecurity. This DC-based coalition of pharma and biotech companies works to ensure medical countermeasures are available to the public. Obviously, during times like this, it could come in beneficial.
While there were no follow-up announcements on March 17, shares managed to jump during premarket trading. HTBX stock has had a history of fading after a gap up so it will be interesting to see how it fairs the rest of this week. For now, the penny stock has managed to see its second consecutive day of premarket momentum.
Coronavirus Penny Stocks To Buy [or avoid]: Waitr Holdings
Another one of the coronavirus penny stocks we talked about on Monday was Waitr Holdings (WTRH-Stock Report). This comes amid a speculative idea that quarantines and lock-down will limit access to food. While this is true, we’ve also seen cities like New York and San Fransisco shut down in-house dining but still allow delivery. Waitr focuses on exactly this. After acquiring Bite Squad, the company stands next to the likes of GrubHub and UberEats. Between Waitr and Bite Squad, the company has operations in 640 cities across the country.
What’s more, is that it has finally started reporting more favorable operating results. Waitr reported a 103% increase in revenue to $43.1 million during the quarter along with a slimmer net loss of $0.28 per share compared to $0.52 per share the same period in 2018. While the company did own up to the fact that things were a bit lax before, CEO Carl Grimstad appears to be ready to get things back on track this year.
- Penny Stocks Rising On Coronavirus Fears; 5 To Watch
- Gold Penny Stocks Bounce Sharply On Monday; 4 To Watch
“We have made tremendous progress on these fronts so far in 2020, and I expect these initiatives will result in the Company achieving positive cash flow, beginning in the first quarter of 2020,” he said. I guess we’ll see how Waitr delivers on this promise.
Coronavirus Penny Stocks To Buy [or avoid]: iFresh Inc.
iFresh (IFMK-Stock Report) has also been one of the speculative penny stocks to watch during the coronavirus outbreak. The company operates grocery stores on the East Coast specializing in Asian products. The hook is that it also offers online shopping and delivery in the areas of its stores. So, you can see the quarantine/coronavirus angle here. But like I said above, some companies try to do whatever they can to get more exposure to this hype.
Well, after weeks of speculation on food delivery, the company did something else this week. iFresh announced that it signed a purchase agreement to acquire 70% interest in a face mask company. After paying $600k, iFresh will be the proud new owners of 70% interest in Xiamen DL Medical Technology Co. They specialize in “research and development of technology, manufacturing, and distribution of medical and non-medical protective masks, cotton spinning textiles, knitwear, daily necessities, kitchen and toilet appliances, and other related goods.”
Mr. Long Deng, Chief Executive Officer and Chairman of iFresh commented: “This acquisition is a major step forward in broadening our business into a new market. Our board of directors have been extremely supportive of the transaction given the current COVID-19 outbreak and the surging demand of medical products.”
Coronavirus Penny Stocks To Buy [or avoid]: Aytu BioScience, Inc.
Aytu BioScience, Inc. (AYTU-Stock Report) continues to surge this month. After hitting 52-week lows on March 9, shares have been on the move. Not only has AYTU reached highs of nearly $3, but the coronavirus penny stock also managed to rebound after consolidating late last week.
The excitement has centered around the company’s latest move to secure a position in the coronavirus wars. Aytu recently entered into an exclusive distribution agreement for the right to commercialize a clinically validated and commercially used coronavirus IgG/IgM Rapid Test. The company’s test was recently featured on a local NBC news station in Colorado. It demonstrated the ability to test for things like COVID-19 and report results in 2-10 minutes.
Furthermore, Josh Disbrow, the CEO of AYTU Bioscience explained, ” Very few tests have been FDA-approved despite the big need. Tests are getting approved but rapid point-of-care tests have not yet been approved. So if this can get approved, it would be among the first, if not the first.”